Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208992 | 0.85 | NPC1 (0.64) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3209903 | 0.83 | HPGD (0.52) | ALDH1A1KMT2ANPC1HPGDRAB9A | |
| SCHEMBL8277246 | 0.80 | ATM (0.58) | ALDH1A1LMNAHPGDMAPTATM | |
| SCHEMBL503308 | 0.79 | PLA2G4B (0.58) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3203319 | 0.79 | NPC1 (0.74) | ALDH1A1LMNAKMT2ANPC1HPGD | |
| SCHEMBL3206438 | 0.79 | KMT2A (0.60) | LMNAKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8290681 | 0.78 | SMN1; SMN2 (0.76) | ALDH1A1LMNAKMT2ANPC1HPGD | |
| SCHEMBL8352827 | 0.78 | SMN1; SMN2 (0.60) | ALDH1A1LMNAKMT2ANPC1HPGD | |
| SCHEMBL3199912 | 0.78 | ATM (0.60) | ALDH1A1LMNANPC1HPGDRAB9A | |
| SCHEMBL3190312 | 0.78 | S1PR1 (0.60) | ALDH1A1LMNAKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | ALDH1A1 1501/4885LMNA 133/4885KMT2A 4332/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | ALDH1A1 3543/4885LMNA 277/4885KMT2A 4216/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | ALDH1A1 1151/4885LMNA 105/4885KMT2A 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.